Drug Sponsors

RaNA Therapeutics relaunches as Translate Bio

Monday, July 3, 2017

RaNA Therapeutics has relaunched as Translate Bio (www.translate.bio). The new name stems from the company’s focus on pioneering the translation of RNA science into therapeutics promoting healthy gene expression for people living with debilitating genetic diseases. In addition to its new name, the company also announced the recent leadership appointments of Michael Heartlein, Ph.D., as chief technical officer and Brian Fenton as chief business officer.

[Read More]

Philips to acquire The Spectranetics Corporation

Friday, June 30, 2017

Royal Philips, a global leader in health technology, and The Spectranetics Corporation, a U.S.-based global provider of vascular intervention and lead management solutions, have entered into a definitive merger agreement. Pursuant to the agreement, Philips will commence a tender offer to acquire all of the issued and outstanding shares of Spectranetics for $38.50 per share, to be paid in cash upon completion. This represents a 27% premium to Spectranetics closing price on June 27, 2017. The implied enterprise value is approximately EUR 1.9 billion, inclusive of Spectranetics’ cash and debt. The board of directors of Spectranetics has approved the transaction and recommends the offer to its shareholders. The transaction is expected to close in the third quarter of 2017.

[Read More]

Pfizer breaks ground on new R&D facility in Missouri, to hire 80

Thursday, June 29, 2017

Pfizer, a biopharmaceutical company, broke ground on a state-of-the art Research and Development (R&D) and process development facility at 875 W. Chesterfield Parkway, Chesterfield, MO. The new campus will be owned by Pfizer and will bring together more than 450 employees who currently work at multiple locations which the company leases in the St. Louis area. Pfizer expects to hire an additional 80 employees over the coming years to support research at the site. Construction is expected to be complete by mid-2019.

[Read More]

Flagship Pioneering launches Sigilon Therapeutics

Monday, June 26, 2017

Flagship Pioneering, a fully-integrated life science innovation enterprise, announced the launch of Sigilon Therapeutics. Sigilon Therapeutics is a biopharmaceutical company that discovers and develops category-defining biocompatible encapsulated cell therapies. Sigilon Therapeutics’ discovery platform combines cell engineering and revolutionary biocompatible Afibromer technology, a new class of implantable biomaterials that do not trigger fibrosis.

[Read More]

AmerisourceBergen reorganizes

Monday, June 19, 2017

AmerisourceBergen announced a new organizational structure designed to further align the organization to its customer needs in a more seamless and unified way, while supporting corporate strategy and accelerating growth. The company’s customer-facing offerings will now be aligned under two groups:

[Read More]

Irvine Scientific adds new R&D center of excellence

Wednesday, June 14, 2017

Irvine Scientific, a leader in the development and manufacture of cell culture media, announced the expansion of its Orange County, California, offices and laboratories, with the addition of a 40,000 square foot purpose-built R&D center at 17112 Armstrong Ave, Irvine, California. The growth of the company is in response to increased customer demand for Irvine Scientific’s cell culture and media reagents, and follows the significant expansion of its R&D facilities less than five years ago.

[Read More]